These findings suggest that JTTZF is a therapeutic agent in inhibiting STING‐restored metabolic homeostasis for the management of obesity‐related T2D via the cGAS‐STING/TBK1/NF‐κB pathway. This evidence concerns the gene TBK1 and type 2 diabetes mellitus.